Wof is a monoclonal anti CD20 antibody used in treating NHL
**Core Concept**
The question is testing the student's knowledge of monoclonal antibodies used in the treatment of Non-Hodgkin's Lymphoma (NHL). CD20 is a cell surface antigen expressed on B cells, making it a target for therapies aimed at depleting malignant B cells.
**Why the Correct Answer is Right**
Wof (not a commonly used name) is not the correct name of the drug. However, Rituximab is a monoclonal antibody that targets CD20 and is widely used in treating NHL. It works by binding to CD20 on the surface of B cells, leading to their depletion through a combination of mechanisms including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis. Rituximab's efficacy in NHL has been well-established, making it a cornerstone in the treatment of this disease.
**Why Each Wrong Option is Incorrect**
**Option A**: This option is incorrect as it is not a known monoclonal antibody targeting CD20.
**Option B**: This option is incorrect as it is not a widely used monoclonal antibody in NHL treatment.
**Option C**: This option is incorrect as it is not a commonly recognized monoclonal antibody targeting CD20.
**Clinical Pearl / High-Yield Fact**
Rituximab's efficacy in NHL is well-established, but it can cause severe infusion reactions in some patients. Pre-treatment with antipyretics and corticosteroids can help mitigate this risk.
**Correct Answer: C. Rituximab**